{"id":27497,"date":"2021-06-10T06:10:53","date_gmt":"2021-06-10T06:10:53","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=27497"},"modified":"2022-12-11T23:16:16","modified_gmt":"2022-12-11T23:16:16","slug":"prescient-therapeutics-investor-replay-10-june","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/","title":{"rendered":"Prescient Therapeutics Investor Replay &#8211; 10 June"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmb3c0ee5 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm29d1c66\" class=\"wp-block-gutentor-m4 section-gm29d1c66 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmc1a9bf\" class=\"wp-block-gutentor-m4-col col-gmc1a9bf gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gmc1a9bf\" class=\"section-gmc1a9bf gutentor-col-wrap\">\n<h2 class=\"has-text-align-center has-white-color has-text-color wp-block-heading\" style=\"font-size:33px\">Prescient Therapeutics Investor Briefing<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm82c3d32\" class=\"wp-block-gutentor-m4 section-gm82c3d32 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmec1deb\" class=\"wp-block-gutentor-m4-col col-gmec1deb gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmec1deb\" class=\"section-gmec1deb gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"575\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/08\/Screen-Shot-2022-07-20-at-11.35.jpg\" alt=\"\" class=\"wp-image-27819\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/08\/Screen-Shot-2022-07-20-at-11.35.jpg 1024w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/08\/Screen-Shot-2022-07-20-at-11.35-300x168.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/08\/Screen-Shot-2022-07-20-at-11.35-768x431.jpg 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/718968273?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm7372b1\" class=\"wp-block-gutentor-m4-col col-gm7372b1 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm7372b1\" class=\"section-gm7372b1 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of Scientific Affairs Dr Rebecca Lim provide an overview of Prescient\u2019s new cell therapy enhancement platform CellPryme.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, they discuss:<\/p>\n\n\n\n<ul class=\"white wp-block-list\"><li>An overview of Prescient\u2019s new platform CellPryme, for enhancing cell therapies;<\/li><li>How CellPryme complements Prescient\u2019s existing next gen CAR-T platform OmniCAR<\/li><li>The compelling data for the CellPryme platform and next steps toward commercialisation.<\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 10 June 2022 at 12:30pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gmd9be851 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"speak has-text-color wp-block-heading\" style=\"color:#ffcc00\">Featured Speakers<\/h4>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\"><\/h3>\n\n\n\n<section id=\"gm336931a\" class=\"wp-block-gutentor-m4 section-gm336931a gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm58dc67\" class=\"wp-block-gutentor-m4-col col-gm58dc67 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm58dc67\" class=\"section-gm58dc67 gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gmed63e6\" class=\"wp-block-gutentor-m4-col col-gmed63e6 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmed63e6\" class=\"section-gmed63e6 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmf80fd7\" class=\"wp-block-gutentor-m4-col col-gmf80fd7 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmf80fd7\" class=\"section-gmf80fd7 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full is-resized speaker-img\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim-2-scaled-e1670798280688.jpg\" alt=\"\" class=\"wp-image-29115\" width=\"300\" height=\"306\"\/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Dr Rebecca Lim<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">Senior Vice President of Scientific Affairs <\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm3de146\" class=\"wp-block-gutentor-m4-col col-gm3de146 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm3de146\" class=\"section-gm3de146 gutentor-col-wrap\"><\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":27381,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-27497","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-10T06:10:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-11T23:16:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1914\" \/>\n\t<meta property=\"og:image:height\" content=\"1074\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"Prescient Therapeutics Investor Replay &#8211; 10 June\",\"datePublished\":\"2021-06-10T06:10:53+00:00\",\"dateModified\":\"2022-12-11T23:16:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\"},\"wordCount\":206,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\",\"name\":\"Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png\",\"datePublished\":\"2021-06-10T06:10:53+00:00\",\"dateModified\":\"2022-12-11T23:16:16+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png\",\"width\":1914,\"height\":1074},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Investor Replay &#8211; 10 June\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/","og_site_name":"PTX Therapeutics","article_published_time":"2021-06-10T06:10:53+00:00","article_modified_time":"2022-12-11T23:16:16+00:00","og_image":[{"width":1914,"height":1074,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png","type":"image\/png"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"Prescient Therapeutics Investor Replay &#8211; 10 June","datePublished":"2021-06-10T06:10:53+00:00","dateModified":"2022-12-11T23:16:16+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/"},"wordCount":206,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/","name":"Prescient Therapeutics Investor Replay - 10 June - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png","datePublished":"2021-06-10T06:10:53+00:00","dateModified":"2022-12-11T23:16:16+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Screen-Shot-2022-07-20-at-11.35.56-am.png","width":1914,"height":1074},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-10-june\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Investor Replay &#8211; 10 June"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/27497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=27497"}],"version-history":[{"count":15,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/27497\/revisions"}],"predecessor-version":[{"id":29122,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/27497\/revisions\/29122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/27381"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=27497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=27497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=27497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}